Dose Escalation Data from transcendIT-101, Ascendis : compar

- Early signs of clinical activity were observed in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab;...

Related Keywords

Copenhagen , Køavn , Denmark , Germany , New Jersey , United States , Palo Alto , California , Redwood City , Heidelberg , Baden Wüberg , Berlin , Diwakar Davar , Ascendis Pharma , Stina Singel , Head Of Clinical Development , Society For Immunotherapy Of Cancer , University Of Pittsburgh Medical Center , Pittsburgh Medical Center , Senior Vice President , Clinical Development , First In Human Dose Escalation , Dose Expansion Study , Combination With Pembrolizumab , Patients With Locally Advanced , Metastatic Solid Tumor Malignancies , Initial Results From Phase , Nasdaq Asnd ,